Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 ...

Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new ...

Using the ProFoundry platform and Novartis' expertise, the partners will identify novel proteins and drug targets for cardiovascular disease.

Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to ...

ProFound Therapeutics enters multi-year strategic collaboration with Novartis to discover and develop novel therapeutics for cardiovascular disease: Cambridge, Massachusetts Frida ...

ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease Provided by GlobeNewswire Jun 26, 2025, 10:30 ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Novartis entered into a four-year partnership with Flagship Pioneering’s ProFound Therapeutics to discover and develop novel protein therapies for cardiovascular conditions.. The deal, announced ...

Chip Wilson, the visionary entrepreneur who fundamentally reshaped the world of athletic apparel with Lululemon, is now ...

The Conference Forum announced today the first set of keynotes for the 15th annual DPHARM: Disruptive Innovations to Modernize Clinical Research conference, taking place September 16-17, 2025, at the ...

CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProFound™ Therapeutics, a company pioneering the expanded human proteome to develop first-in-class medicines for multiple diseases, today announced ...

The global Eye Infections Treatment Market is projected to be valued at USD 8,160.6 million in 2025, reaching USD 11,400.7 million by 2035, with a compound annual growth rate (CAGR) of 4.7% during the ...